The previous argument suggested that the exclusive use of ERK2, as opposed to ERK1, in drug-addicted melanoma cells might result from preferential genetic (or physical) interactions of BRAF complex proteins with ERK2 rather than ERK1 [33]. This evidence concerns the gene MAPK3 and melanoma.